PTC funding has helped a new Tau therapy advance and to develop new a collaboration.

Since receiving the Part the Cloud (PTC) Award in 2015, C2N Diagnostics has completed the Phase I safety and tolerability clinical study of its anti-tau antibody (C2N-8E12, now known as ABBV-8E12). This study enrolled 30 individuals with progressive supranuclear palsy (PSP), a serious and progressive neurodegenerative disorder characterized by tau pathology in the brain. Funding from Alzheimer’s Association was instrumental for both timely and effective execution of this Phase I study. Many prospective commercial partners with whom C2N communicated valued Alzheimer’s Association confidence and commitment to the C2N program. In 2015, C2N entered into an exclusive partnership with a leading global biopharmaceutical company, AbbVie Inc., for the continued clinical development and worldwide commercialization of ABBV-8E12.

C2N presented the top-line results from the Phase I safety study of ABBV-8E12 in December 2016 at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego, CA. The results showed that ABBV-8E12 has an acceptable safety and tolerability profile among subjects with PSP receiving a single dose of the drug. Metabolism and brain penetration of ABBV-8E12 were as predicted and consistent with drugs of similar type to ABBV-8E12. Two new, multinational phase 2 studies of ABBV-8E12 are currently enrolling. One study is enrolling patients with PSP, and the other is enrolling patients with early Alzheimer’s disease. In the treatment indication of PSP, ABBV-8E12 has received both Orphan Drug Designations in the U.S. and Europe as well as a Fast Track Designation from the U.S. Food and Drug Administration. C2N is grateful to the Alzheimer’s Association and its PTC program for providing critical funding to its tau therapeutic program. This support has helped accelerate the development of a potentially promising therapeutic approach to Alzheimer’s disease.